



Stichting Leukemie.nl (Dutch Leukemia Foundation)

P.O. Box 2024, 3800 CA Amersfoort, The Netherlands
Tel.: +31-33-479.80.60, Fax: +31-33-432.00.62
www.leukemie.nl, info@leukemie.nl

Donations? 65.69.32.945

Stichting Leukemie.nl (Dutch Leukemia Foundation)
in Amersfoort, The Netherlands or from abroad
IBAN number: NL68INGB0656932945, BIC code: INGBNL2A

A large vertical banner with a dark background on the left and a lighter, hazy background on the right. It features silhouettes of a family walking on a beach, similar to the image above. The text "Stichting leukemie.nl" and "Dutch Leukemia Foundation" is written in white and red. At the bottom, it says "Making progress step by step" and includes a small version of the logo and a trail of red footprints.

Stichting leukemie.nl
Dutch Leukemia Foundation

**Making progress
step by step**

www.leukemie.nl

Organisation

The Dutch Leukemia Foundation was founded in 2005 and is the national leukemia foundation for The Netherlands. The organisation came into being when Martijn Beukhof, then 17 years old, was diagnosed with acute leukemia. Since then, Martijn has fully recovered and together with others, he now is an active member of the foundation.

Our aims

The Dutch Leukemia Foundation provides financial support for leukemia research. In addition, the foundation supports leukemia patients during and after their treatment and provides information for the general public. Our projects are financed through fundraising aimed at individuals, institutions and companies.

Dutch Leukemia Foundation invests in:

- pilots and trials of promising leukemia research programmes
- the infrastructure needed for research
- the latest technologies in the field of research

Medical advisors

- **prof. dr. A. Hagenbeek**

*Academic Medical Center Amsterdam
and University Medical Center Utrecht*

- **prof. dr. B. Löwenberg**

Erasmus University Medical Center Rotterdam

- **prof. dr. P.C. Huijgens**

VU University Medical Center Amsterdam

Adopted project

Suicide gene therapy in leukemia after allogeneic stem cell transplantation by prof. dr. A. Hagenbeek

In the University Medical Center in Utrecht (UMCU), Department of Hematology, the first clinical gene therapy study will be initiated shortly. The aim of the treatment is to induce remissions in patients with a relapsed hematological malignancy after allogeneic stem cell transplantation by genetically modified donor lymphocytes. A suicide gene is introduced in the donor lymphocytes and after infusion into the patient the graft-versus-leukemia/lymphoma/multiple myeloma reaction is given the opportunity to develop. As soon as the concomitant graft-versus-host reaction gets too severe, the prodrug is given, which will induce suicide in the genetically modified lymphocytes, which are responsible for the alloreactivity. A feasibility study of 10 patients will be done over a period of 2 years duration.

For more information:

www.leukemie.nl

Support
the Dutch
Leukemia
Foundation